Hong Kong · Delayed Price · Currency is HKD BioDlink International Company Company Description
BioDlink International Company Limited, an investment holding company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally.
The company offers Pusintin, a bevacizumab injection to treat advanced, metastatic or recurrent non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; and cervical cancer.
It also provides Tazian, a temozolomide capsule for the treatment of newly diagnosed glioblastoma multiforme or anaplastic astrocytoma that recurs or progresses after conventional treatment.
In addition, the company develops TAB014 that has completed Phase III clinical trial for the treatment of wet age-related macular degeneration (wAMD); TAE020, which is in preclinical trial to treat acute myeloid leukemia; and TAC020, which is in preclinical trial for the treatment of various solid tumors.
Further, it is involved in contract development and manufacturing organization (CDMO)/contract manufacture organization (CMO) business; and license-out of self-developed biological drugs.
The company was formerly known as TOT BIOPHARM International Company Limited and changed its name to BioDlink International Company Limited in July 2025.
BioDlink International Company Limited was incorporated in 2009 and is headquartered in Suzhou, China.
| Country | Hong Kong |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 604 |
| CEO | Jun Liu |
Contact Details
Address: No. 120 Changyang Street Suzhou, 215024 China | |
| Phone | 86 512 6296 5186 |
| Website | biodlink.com |
Stock Details
| Ticker Symbol | 1875 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | HK0000545266 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Shan Fu M.A. | Executive Chairperson of the Board |
| Ben Xiao | Group Vice President of Finance and Investor Relations |
| Dr. Jian Bo Zhang | Chief Operating Officer |
| Li Yin | Chief Technology Officer |
| Yifan Chen | Joint Company Secretary |